ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 2251 • ACR Convergence 2023

    Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study

    Peter C. Taylor1, David Walsh2, Tsutomu Takeuchi3, Bruno Fautrel4, Janet Pope5, Koji Kato6, Arathi Setty6, Tianming Gao6, Diane Caballero7, Ralph Lippe8 and Arthur Kavanaugh9, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Sorbonne Université APHP, Paris, France, 5University of Western Ontario, London, ON, Canada, 6AbbVie, Inc., North Chicago, IL, 7AbbVie, Inc., Chicago, IL, 8AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 9University of California San Diego, School of Medicine, Riverside, CA

    Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via…
  • Abstract Number: 0072 • ACR Convergence 2023

    Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons

    Marie Naingeon1, Samuel Bitoun2, Matthieu roulleaux Dugage1, Caroline de Oliveira1, Caroline Berthot1, Xavier Mariette3, Nathalie Chaput1 and Gaetane Nocturne4, 1LIO, Department of Medicine, Gustave Roussy Université Paris Saclay, Villejuif, France, 2CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, 3Université Paris-Saclay, Le Kremlin-Bicêtre, France, 4APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Immunosenescence is a global remodeling of immune functions that has been first described with aging. It can also occur in pathologies associated with chronic…
  • Abstract Number: 0775 • ACR Convergence 2023

    Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study

    Amy Peeters, C.A.J Michielsens, Elien Mahler, Lise Verhoef, Alfons den Broeder, Nathan den Broeder and Noortje van Herwaarden, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are effective in PsA and axial SpA, but are associated with increased infections risk, patient burden and high costs.…
  • Abstract Number: 1557 • ACR Convergence 2023

    De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome

    Sinem Nihal Esatoglu1, Ozge Sonmez2, Didar Ucar3, Elif Kaymaz4, Yesim Ozguler5, Serdal Ugurlu6, Emire Seyahi1, Melike Melikoglu1, Izzet Fresko7, Vedat Hamuryudan1, Ugur Uygunoglu8, Zekayi Kutlubay9 and Gulen Hatemi1, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Istanbul, Turkey, 7Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 8Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey, 9Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Dermatology, Istanbul, Turkey

    Background/Purpose: Monoclonal antibody tumor necrosis factor alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used biological agents in the treatment of Behçet's syndrome…
  • Abstract Number: 2474 • ACR Convergence 2023

    Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience

    Ilaria Maccora1, Valerio Accardo2, Marco Cattalini3, ilaria Pagnini4, Andrea Taddio5, Edoardo Marrani6, francesco La Torre7, Matteo Trevisan8, Maria Vincenza Mastrolia9 and Gabriele Simonini10, 1PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, 2University of Florence, Florence, Italy, 3Spedali Civili di Brescia, Brescia, Italy, 4Meyer Children's Hospital IRCCS, Florence, Italy, 5Rheumatology Unit, IRCCS Burlo Garofalo, Trieste, Italy, 6University of Florence, Firenze, Italy, 7Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy, 8IRCCS Burlo Garofalo, Trieste, Italy, 9NEUROFARBA Department, University of Florence, Florence, Italy, 10Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy

    Background/Purpose: TNF inhibitors (TNFi) have dramatically changed the prognosis of Juvenile Idiopathic Arthritis (JIA). However, once achieved disease remission, it is not clear how and…
  • Abstract Number: 073 • 2023 Pediatric Rheumatology Symposium

    Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy

    Claire Yang1, Natalie Rosenwasser2, Xing Wang2, Zheng Xu2, Joshua Scheck2, Ramesh Iyer3 and Yongdong (Dan) Zhao3, 1University of Washington School of Medicine, Seattle, WA, 2Seattle Children's Hospital, seattle, WA, 3University of Washington, Seattle, WA

    Background/Purpose: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disease requiring immunosuppressive therapy in half of patients. Monoclonal Tumor Necrosis Factor inhibitors (TNFi) are…
  • Abstract Number: 096 • 2023 Pediatric Rheumatology Symposium

    DADA2 – a Case Series from North India

    Manjari Agarwal, Jyotsna verma, ratna puri and Sujata Sawhney, Sir Ganga Ram Hospital, New Delhi, India

    Background/Purpose: We present a series of children previously diagnosed and managed as Polyarteritis nodosa at our unit. Due to ease of availability of mutation analysis…
  • Abstract Number: 0426 • ACR Convergence 2022

    The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis

    Jesus Diaz1, Guillermo Quiceno2, Cathy Lee Ching3 and Adela Castro4, 1Hamilton Medical Center, Chattanooga, TN, 2UT Southwestern Medical Center, Dallas, TX, 3University of Mississippi Medical Center, Jackson, MS, 4Hamilton Physician Group-Specialty Care, Dalton, GA

    Background/Purpose: There is an unmet medical need for the treatment of patients with active ankylosing spondylitis (AS) who have an inadequate response to NSAIDs. Prior…
  • Abstract Number: 1010 • ACR Convergence 2022

    Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies

    Xenofon Baraliakos1, Pedro Machado2, Lars Bauer3, Bengt Hoepken3, Mindy Kim4, Thomas Kumke3, Rachel Tham5 and Martin Rudwaleit6, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2University College London, London, United Kingdom, 3UCB Pharma, Monheim am Rhein, Germany, 4UCB Pharma, Smyrna, GA, 5UCB Pharma, Slough, UK, Overland Park, KS, 6University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

    Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
  • Abstract Number: 1891 • ACR Convergence 2022

    Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial

    Walter P Maksymowych1, Louis Bessette2, Robert G Lambert3, Amanda Carapellucci4 and Tom Appleton5, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 3University of Alberta, Edmonton, AB, Canada, 4CARE Arthritis LTD, Edmonton, AB, Canada, 5The University of Western Ontario, London, ON, Canada

    Background/Purpose: Recent RCTs demonstrated that TNFα inhibition has no effect on pain and MRI-detected synovitis or bone marrow lesions in patients with erosive hand OA.…
  • Abstract Number: 0430 • ACR Convergence 2022

    The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis

    Mark Siderius1, Anneke Spoorenberg2, Freke Wink3 and Suzanne Arends2, 1University Medical Centre Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands, 3Medical Center Leeuwarden, Leeuwarden, Netherlands

    Background/Purpose: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis…
  • Abstract Number: 1137 • ACR Convergence 2022

    MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy

    Kristin Wipfler1, Joshua Baker2 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: MHC class I polypeptide-related sequence A (MICA) is a protein involved in the activation of NK and T cells. Variants within the MICA gene…
  • Abstract Number: 1966 • ACR Convergence 2022

    Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Eva van Geel1, Bafrin Abdulmajid1, Annelies Blanken2 and Michael Nurmohamed3, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands

    Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
  • Abstract Number: 0543 • ACR Convergence 2022

    An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis

    Martin Rudwaleit1, Filip Van den bosch2, Helena Marzo-Ortega3, Victoria Navarro-Compán4, Rachel Tham5, Thomas Kumke6, Lars Bauer6, Mindy Kim7 and Lianne Gensler8, 1University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 2Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 3Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, 4Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 5UCB Pharma, Slough, UK, Overland Park, KS, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Smyrna, GA, 8Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: In clinical trials of axial spondyloarthritis (axSpA), composite measures such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response criteria, Assessment of Spondyloarthritis international…
  • Abstract Number: 1210 • ACR Convergence 2022

    Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis

    Namrata Singh1, Alexander Peterson2, Aaron Baraff2, Ajay Gopal3, Nicholas Smith4, Jennifer Barton5, Jeffrey Curtis6 and Noel Weiss3, 1University of Washington, Bellevue, WA, 2VA Puget Sound, SEATTLE, WA, 3University of Washington, Seattle, WA, 4VA Puget Sound/University of Washington, Seattle, WA, 5VA Portland Health Care System/OHSU, Portland, OR, 6University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) are associated with lymphoma development [1]. Whether the decrease…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology